SUBSCRIBE
SUBSCRIBE

Lori Ellis

Lori was formerly head of insights at BioSpace. She has been part of an award-winning marketing team and has won a Muse Creative award, a Vega award and several Adobe awards in collaborative team projects for her audio narration work. While she has covered all elements of the drug development process, her primary focuses are women’s health issues, the economic climate, and the ever-evolving impact of technology – specifically artificial intelligence – on the pharmaceutical industry.

PODCAST
What Do AI and Hammers Have in Common?
In this episode of Denatured, BioSpace’s head of insights Lori Ellis and Colin Zick, partner at Foley Hoag LLP, spend time discussing some of the points brought up in the Bioprocessing Summit last month. They explore the connections between hammers, AI, The Planet of the Apes and monoliths.
September 18, 2025
 · 
1 min read
 · 
Lori Ellis
Modern data center with AI server racks connected by glowing blue lines, representing artificial intelligence, advanced computing, and data processing.
Drug Development
If Data Is the New Oil, AI Is the Refinery
The 2025 Bioprocessing Summit revealed knowledge gaps and changing mindsets. As some companies look towards the future, others struggle with the present and past.
September 8, 2025
 · 
5 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH TACONIC BIOSCIENCES
The ‘Research Safety Net’ Saving Scientists from Funding Crisis
In this episode presented by Taconic Biosciences, BioSpace’s head of insights Lori Ellis discusses how preclinical research companies are helping drug developers navigate the current challenging funding environment with Mike Garrett, CEO.
September 4, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses clinical trial fail rates and AI’s potential to reduce preclinical costs with Mutlu Dogruel, VP of AI and Mark Mackey, CSO of Cresset.
August 21, 2025
 · 
1 min read
 · 
Lori Ellis
PODCAST
The Hidden Patent Crisis That Could Break Biotech: What Every CEO Needs to Know
In this episode of Denatured, BioSpace’s head of insights Lori Ellis discusses the ‘enormous implications’ of patent policy changes with Aaron Cummings and Anne Li of Brownstein Hyatt Farber Schreck.
August 14, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH CRESSET
From Chat Bots to World Order: The Race for the 21st Century’s Operating System
In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses the emerging geopolitical battle for AI supremacy and global AI governance with Mutlu Dogruel, VP of AI and Mark Mackey, CSO of Cresset.
August 7, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH IQVIA
We Don’t Own Patient Data–We’re Just Babysitting It
In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the concerns and opportunities of patient data driving AI tasks with Louise Molloy, associate director medical information and pharmacovigilance.
July 31, 2025
 · 
1 min read
 · 
Lori Ellis
Job interview, recruitment concepts. Row of chairs with one odd one out. Job opportunity. Blue chair in spotlight. Business leadership. 3D Rendering
FDA
From Expertise to Empty Chairs: The FDA’s Self-Inflicted Crisis
While FDA Commissioner Marty Makary emphasizes learning and humility, the FDA has systematically removed the very experience that would make change possible.
July 23, 2025
 · 
7 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH ECLIPSEBIO
Why Countries Are Racing To Build mRNA Factories While America Hesitates on Next-Gen Vaccines
In this episode presented by Eclipsebio, BioSpace’s head of insights Lori Ellis continues the discussion on mRNA and srRNA with Andy Geall of Replicate Bioscience and Alliance for mRNA Medicines and Pad Chivukula of Arcturus Therapeutics.
July 22, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH IQVIA
AI Is Taking Over Drug Safety Monitoring–But There’s One Thing It Can’t Replace
In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the evolving role of local qualified persons for pharmacovigilance with ⁠Ana Pedro Jesuíno⁠, global head local QPPV network at IQVIA.
July 17, 2025
 · 
1 min read
 · 
Lori Ellis
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
Despite the FDA commissioner’s promises of partnership and collaboration, personnel changes and continued federal cuts create uncertainty for an industry already struggling with nearly half a decade of investment scarcity.

July 14, 2025
 · 
6 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH ECLIPSEBIO
The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
In this episode presented by Eclipsebio, BioSpace’s head of insights Lori Ellis discusses mRNA and srRNA with Andy Geall of Replicate Bioscience and Alliance for mRNA Medicines, and Pad Chivukula of Arcturus Therapeutics.
July 10, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH IQVIA
Understanding the FDA’s AI Guidance in Pharmacovigilance
In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the FDA’s first draft guidance for AI in drug development, published in January 2025, with Archana Hegde, senior director, pv systems and innovations at IQVIA.
July 1, 2025
 · 
1 min read
 · 
Lori Ellis
Business
Navigating Funding Freezes and AI Frontiers
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis discusses key themes from BIO and DIA, including the funding environment, with Rich Daly, CEO of Catalyst Pharmaceuticals, Peter Ronco, CEO of Emmes Corporation, and Phil Vanek, founder of Redline Bio Advisors.
June 20, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH IQVIA
AI’s Role in Decoding the FDA’s New Regulatory Communications
In this episode of Denatured, presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses how AI transformation can help organizations navigate a rapidly evolving regulatory environment with senior director of regulatory innovation and technology, Michelle Gyzen.
June 5, 2025
 · 
1 min read
 · 
Lori Ellis
Load More